Key facts
- Singapore treats this as standard of care. The Ministry of Health and HSA say genotyping for HLA-B*1502 before starting carbamazepine in new patients of Asian ancestry is the standard (HSA).
- Ancestry matters, not where you live. A person of Thai or Han Chinese descent carries the same risk in London as in Bangkok, and a European does not acquire it by moving here.
- It is a one-time test. The result does not change, so it is done once and belongs in your records for life.
- The point is to keep the medicine available, not to frighten people away from it. Most people test low risk and can use a cheap, effective drug.
- Allopurinol has its own version of this story, with a different gene variant and the same geography.
- What you watch for is a rash with something else attached: fever, a sore mouth, sore eyes, blistering, or feeling genuinely unwell.
- A rash in the first weeks is a call-someone event. Not a wait-and-see, and not a stop-and-say-nothing.
It starts in the third week. A rash, which by itself would mean very little, except that you also feel unwell in a way that does not match a rash, your mouth is sore, and your eyes are gritty.
Most articles you might read about this medicine mention, somewhere near the bottom, that serious skin reactions are rare. What almost none of them say clearly is that “rare” was measured in populations that look nothing like most people reading this page in Bangkok, Kuala Lumpur, Manila or Singapore.
The variant, and why the footnote is in the wrong place
There is a gene variant called HLA-B*15:02. In people who carry it, carbamazepine can trigger Stevens-Johnson syndrome and toxic epidermal necrolysis, which are severe reactions where the skin and the linings of the mouth and eyes blister and detach. They carry significant mortality and long-term consequences.
The variant is common in Han Chinese, Thai, Malay and Filipino populations. It is rare in people of European descent.
That single geographic fact explains everything about how this information is presented. American and British health writing is produced for readers who mostly do not carry the variant, so it is accurate for them to treat it as an unusual footnote. When that writing travels, the proportion stays and the population changes, and something that should be the first thing you are told becomes the last line of a side-effects list.
The US Food and Drug Administration label does say it, directing that patients with ancestry in genetically at-risk populations should be screened for HLA-B*15:02 before treatment.
But the clearest statement comes from closer to home.
What Singapore actually does
In 2013, Singapore’s Ministry of Health announced that genotyping for the HLA-B*1502 allele before starting carbamazepine in new patients of Asian ancestry is considered the standard of care, a recommendation made with HSA in consultation with specialists in neurology, psychiatry and dermatology.
The reason was not theoretical. Between 2003 and 2012, HSA received 131 local serious reports of carbamazepine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis, an average of about fifteen a year in one small country.
HSA has since reminded prescribers to verify a patient’s status before starting treatment and named the laboratories where the test is available, including hospital molecular diagnostic laboratories and HSA’s own tissue typing laboratory.
Now the sentence that should change how this whole subject feels. HSA describes the purpose of the test like this: a one-time genotyping test helps distinguish high-risk patients who should avoid the drug from low-risk patients who are able to continue using this low-cost yet effective medicine.
Read that again, because it is the opposite of how genetic risk is usually presented. The test is not there to take a medicine away from you. It is there so that a cheap, effective, decades-old drug can go on being used by the large majority of people for whom it is perfectly safe, instead of being nervously avoided for everyone. The test protects the medicine as much as the patient.
It is not only carbamazepine
The same pattern appears more than once, which is why this article is about a category rather than a drug.
| Medicine | Variant | Where the risk concentrates |
|---|---|---|
| Carbamazepine | HLA-B*15:02 | Han Chinese, Thai, Malay, Filipino and some South Asian populations |
| Allopurinol | HLA-B*58:01 | Han Chinese, Thai and Korean populations, among others |
| Abacavir | HLA-B*57:01 | Screening is long established internationally, not Asia-specific |
| Oxcarbazepine, phenytoin | Related associations | Chemically related enough that a reaction to one raises questions about the others |
Allopurinol is worth its own paragraph because it is such an ordinary prescription. It is a gout medicine, taken by enormous numbers of people, and it is one of the more common causes of severe cutaneous reactions in this region. A national prospective cohort study in Taiwan looked at screening for HLA-B*58:01 before starting it, and research in Thai patients has reported the same association. You can browse what we list under gout, epilepsy, neurology and pain management.
Lamotrigine belongs in this conversation for a different reason. Its serious rash risk is not principally about this variant; it relates to how treatment is started, which is precisely why it is introduced slowly and why nobody should ever speed that up on their own initiative.
Dapsone has a separate issue again, connected to G6PD deficiency, which is also common across this region and which is a different test for a different problem. Worth knowing the phrase exists; not this article’s subject.
Ancestry, not address
This is the part people get wrong most often, in both directions.
The variant travels with your family, not with your visa. A Malaysian-Chinese engineer who has lived in Rotterdam for twenty years carries whatever they were born with. A British teacher who has lived in Chiang Mai for twenty years does not acquire it by staying.
Which has a practical consequence worth acting on. If you are of Asian descent and living in a country where this testing is not routine, your doctor may simply not have it front of mind. That is a reasonable thing to raise. And if you had the test done in Singapore, keep the result, because it is a fact about you that never expires and that a new clinic in a new country will not otherwise know.
Two honest limits. Testing is not universally available everywhere, and this article is not a basis for demanding it. And a low-risk result is about these specific reactions, not a guarantee about every side effect of every medicine.
What to watch for, and what to do
If you are starting one of these, the first two months are when it matters most.
A rash on its own, itchy and unremarkable, is common with many medicines and usually not this. What raises the concern is a rash with something else attached: fever, feeling genuinely unwell, a sore or ulcerated mouth, sore or red eyes, blistering, or skin that is painful rather than itchy. Involvement of the mouth or eyes is particularly significant.
The right response is to contact whoever prescribed it, or an emergency service if you are unwell, the same day. Not next week’s appointment.
What this article does not tell you to do is stop the medicine yourself. Stopping an antiepileptic abruptly carries its own serious risks, and whether to stop, and how, is a decision for someone with your history in front of them. Make the call, describe what you can see, and let them decide.
Also worth reading
For the wider picture of keeping a neurology prescription steady across borders, see epilepsy medicines and moving across time zones. For how care and testing are arranged locally, see buying medicine in Singapore. For matching a brand you were given elsewhere to what is sold here, see the medicine brand-name decoder.
FAQ
I have taken carbamazepine for years without a problem. Should I be tested?
The recommendation is aimed at new patients starting treatment, because these reactions overwhelmingly happen early. Someone established on it for years has, in effect, already demonstrated the answer. Worth raising at a review rather than worrying about.
Does a positive result mean I can never take anything for epilepsy?
No. It means carbamazepine is not the right choice for you, and that related medicines need care. There are other options, and that is a conversation with a neurologist rather than a dead end.
Is this the same as commercial ancestry or DNA testing?
No. This is a single clinical test looking at one specific marker for one specific prescribing decision, ordered by a doctor and interpreted in that context. Consumer ancestry kits are not a substitute for it.
My family is mixed. Which ancestry counts?
That is exactly the sort of question the test answers better than a family tree does. Mention the mixed ancestry; the point of testing is that it removes the guesswork.
Why is this not routine everywhere in the region?
Availability, cost and health-system priorities differ between countries, and the recommendations differ with them. Singapore is a concrete, documented example rather than a description of every country here.
Sources
- HSA Singapore, recommendations for HLA-B*1502 genotype testing prior to initiation of carbamazepine
- HSA Singapore, reminder to verify HLA-B*1502 status before starting carbamazepine
- PharmGKB, annotation of the FDA label for carbamazepine and HLA-B
- BMJ, use of HLA-B*58:01 genotyping to prevent allopurinol-induced severe cutaneous adverse reactions, Taiwan
- Frontiers in Pharmacology, HLA-B*58:01 and allopurinol-induced cutaneous adverse reactions in Thai patients
This article is general information, checked on 10 August 2026. It contains no doses and no schedules, and it is not a substitute for advice from a clinician who knows your history.
